Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
AMGEN INC incurred term loan of $4 billion with Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, Bank of America, Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, and Goldman Sachs Bank USA and Mizuho Bank, Ltd., as documentation agents.
- Instrument
- term loan
- Principal
- $4 billion
- Counterparty
- Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, Bank of America, Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, and Goldman Sachs Bank USA and Mizuho Bank, Ltd., as documentation agents
- Event
- incurrence
Exact text from the filing
On October 6, 2023, Amgen borrowed $4 billion under the Term Loan Credit Agreement
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
AMGEN INC completed an acquisition involving Horizon Therapeutics plc for $116.50 in cash (closed 2023-10-06).
- Action
- acquisition
- Counterparty
- Horizon Therapeutics plc
- Consideration
- $116.50 in cash
- Closing
- 2023-10-06
Exact text from the filing
of 11:59 p.m. New York City time on October 5, 2023, the business day prior to the occurrence of the Effective Time (the “ Scheme Record Time ”), obtained the right to receive $116.50 in cash in exchange for each Horizon Share (the “ Consideration ”). In respect of the Horizon Shares issued and outstanding as of the Scheme Record Time, Amgen paid an aggregate
View on SEC.gov